Updates in High-Risk HR+ and/or gBRCAm+ Early-Stage Breast Cancer

Downloadable slides on individualizing perioperative treatment for patients with high-risk HR-positive and/or germline BRCA–mutated early-stage breast cancer.
Jennifer K. Litton, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 387 KB
Released: June 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Related Content

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Jamie Carroll, MSN on managing adverse events and promoting adherence to CDK4/6 and PI3K inhibitors, from Clinical Care Options (CCO)

Robert T. Carroll, PhD(c), RN, ACRN Released: July 26, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings